Key Stats for Vertex Pharmaceuticals Stock
- Past-Week Performance: −5%
- 52-Week Range: $363 to $520
- Valuation Model Target Price: $557
- Implied Upside: 26.3% over 2.0 years
Value your favorite stocks like Vertex Pharmaceuticals with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Vertex Pharmaceuticals stock (VRTX) is down about 5% over the past week, but shares closed near $441 per share in the most recent session, up about 0.6% on the day, as the stock attempted to stabilize after several days of selling pressure.
The pullback followed a steady decline earlier in the week, with shares lagging the broader market despite no company-specific negative announcements.
During the week, Wolfe Research upgraded Vertex to Outperform, pointing to improving confidence in the company’s kidney disease pipeline.
The firm highlighted a more constructive outlook for Vertex’s potential IgA nephropathy treatment, supported by clearer pricing benchmarks from competing therapies.
Wolfe also noted Vertex’s plan to use a priority review voucher, which could shorten regulatory timelines.
Despite this positive research update, shares remained lower on the week as investors balanced longer-term pipeline optimism against near-term positioning ahead of the company’s upcoming earnings report.
See analysts’ growth forecasts and price targets for Vertex Pharmaceuticals (It’s free) >>>
Is Vertex Undervalued?
Under valuation model assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 9.1%
- Operating Margins: 46.6%
- Exit P/E Multiple: 23.3x
Based on these inputs, the model estimates a target price of $557, implying 26.3% total upside from the current share price over the next 2.0 years.
Over the next 12 months, performance is closely tied to regulatory milestones for Vertex’s IgA nephropathy program, including approval timing and progress toward commercial readiness.
At the same time, continued stability in the cystic fibrosis franchise remains central, as it anchors earnings and cash flow while providing a foundation for newer programs to scale if approvals move forward.
Developments around pricing frameworks, payer reception, and early market access planning will also shape expectations, as these factors influence how quickly any newly approved therapy could translate into meaningful revenue.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
